Skip to content

FDA Grants RMAT Designation to CAR T Therapy Obe-Cel for Lupus and Lupus Nephritis

By asmithers | Published September 13, 2026

FDA Grants RMAT Designation to CAR T Therapy Obe-Cel for Lupus and Lupus Nephritis

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel), Autolus Therapeutics’ CAR T cell therapy, for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). The designation, announced September 9, 2026, is based on Phase 1b data showing high rates of disease remission in patients with severe, treatment-resistant disease.

video thumbnail

Table of Contents

  • What Happened
  • From Blood Cancer to Autoimmune Disease
  • What the Phase 1 Data Show
  • What Comes Next
  • Why This Matters
  • Conclusion

What Happened

Autolus Therapeutics announced on September 9, 2026, that the FDA granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis, based on Phase 1b data from the ongoing CARLYSLE trial. RMAT designation, created under the 21st Century Cures Act, is intended to accelerate development and regulatory review of regenerative medicine therapies, including cell therapies, for serious or life-threatening diseases, offering sponsors more frequent FDA interaction and potential eligibility for accelerated approval pathways.

From Blood Cancer to Autoimmune Disease

Obe-cel is a CD19-targeting autologous CAR T-cell therapy distinguished by a “fast off-rate” binding domain, designed to reduce the toxicity typically associated with CAR T treatment. It’s already an approved, commercially launched therapy: marketed as Aucatzyl, obe-cel received FDA, EMA, and MHRA approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and launched commercially in the US and UK in 2025. The RMAT designation marks Autolus’s push to extend the same CD19-targeting mechanism, which depletes B cells, into autoimmune disease, where errant B cells are believed to drive conditions like lupus.

What the Phase 1 Data Show

The CARLYSLE trial is an ongoing Phase 1 study evaluating obe-cel in patients with severe, refractory SLE who had exhausted other treatment options. Updated data presented at the American Society of Hematology Annual Meeting in December 2025 showed that among six patients treated at the selected 50-million-cell dose, five of six (83%) achieved remission according to the Definition of Remission in SLE (DORIS) criteria, and half achieved a complete renal response. All patients in the trial had refractory lupus nephritis, and four of six had significantly impaired kidney function at baseline. Responses and remissions were ongoing at a median follow-up of 8.9 months, with no dose-limiting toxicities, no immune effector cell-associated neurotoxicity syndrome (ICANS), and no high-grade cytokine release syndrome reported. Steroids were tapered to low maintenance doses in all patients by month six.

What Comes Next

Autolus has aligned with the FDA on the design of LUMINA, a pivotal Phase 2 trial in lupus nephritis with registrational intent, which is currently enrolling patients across five countries. The company expects to report data from LUMINA in 2028. A further Phase 1 CARLYSLE data update has been submitted for presentation at the American College of Rheumatology Annual Meeting in the fourth quarter of 2026.

Why This Matters

Systemic lupus erythematosus and lupus nephritis remain difficult to treat once patients become refractory to standard immunosuppressive therapy, and current options rarely produce durable, drug-free remission. The CARLYSLE data’s most notable signal is a “deep reset” of the B-cell compartment following a single CAR T infusion, raising the possibility that a one-time cellular therapy could induce lasting remission rather than requiring chronic immunosuppression. For the regenerative medicine field, obe-cel’s expansion from an approved oncology product into autoimmune disease is also a notable proof point for CAR T platforms more broadly: several other CD19-targeting cell therapies are now being tested in autoimmune indications following similar early signals of deep B-cell depletion and drug-free remission.

Conclusion

RMAT designation gives Autolus a more direct regulatory pathway as it moves obe-cel into pivotal testing for lupus nephritis, but with LUMINA data not expected until 2028, this remains an early-stage program. The scale of the CARLYSLE remission data, however, makes this one of the more closely watched CAR T programs moving into autoimmune disease.

Sources

  • GlobeNewswire / Autolus Therapeutics, “Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis” — Read here
  • Autolus Therapeutics, “Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial … at ASH Annual Meeting 2025” — Read here
  • StockTitan, “Autolus Gets FDA RMAT Designation for Obe-cel in Lupus” — Read here
Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on FDA Grants RMAT Designation to CAR T Therapy Obe-Cel for Lupus and Lupus Nephritis

The Russian Method: What the Research Says About Ozonated Saline IV Therapy

By asmithers | Published September 2, 2026

The Russian Method: What the Research Says About Ozonated Saline IV Therapy

Ozonated saline drips — widely known as the “Russian method” of IV ozone therapy — are having a moment of renewed scientific scrutiny. A 2025 cellular study on ozone’s anti-inflammatory effects and a 2026 published rebuttal challenging its clinical relevance have reopened debate over how this decades-old Eastern European technique compares to Western ozone protocols.

Ozone Therapy Treats Chronic Conditions Like Epstein-Barr Virus

Table of Contents

  • What the Russian Method Is
  • How It Differs From Major Autohemotherapy
  • What Recent Research Shows
  • A Live Scientific Debate
  • Why This Matters
  • Conclusion

What the Russian Method Is

The Russian method of ozone therapy refers to the intravenous drip infusion of ozonated physiological saline — sodium chloride solution that has been bubbled with medical-grade ozone gas immediately before administration. Rather than requiring blood to be drawn, ozonated, and reinfused, the ozone is dissolved directly into saline and delivered gradually into the bloodstream over roughly 15 to 30 minutes. The technique originated in the former Soviet Union and remains formalized by the Russian Association of Ozone Therapy as a core protocol, distinct from the “West European method” of major autohemotherapy used more widely in Western Europe, the US, and parts of Latin America.

How It Differs From Major Autohemotherapy

Major autohemotherapy involves drawing a patient’s own blood, mixing it with ozone/oxygen gas outside the body, and reinfusing it — a process requiring specialized equipment and closer procedural monitoring. The Russian method instead ozonates the saline carrier itself, delivering ozone “drop by drop, molecule by molecule” as the solution enters circulation. Proponents describe this as simpler to administer, requiring smaller needles suitable for patients with difficult venous access or on blood thinners, and eliminating the contamination risk associated with handling blood outside the body. The Russian protocol also characteristically uses lower ozone concentrations delivered over a longer duration, based on the rationale that repeated low-dose exposure produces a more consistent antioxidant response than a single high-dose exposure, which can diminish in effectiveness with repeated use.

What Recent Research Shows

A study published in Molecules in September 2025 by researchers at Sapienza University of Rome examined how ozonated saline solution affects microglial cells (the immune cells of the central nervous system) and endothelial cells in laboratory conditions. At low concentrations (1 and 5 μg/NmL), ozonated saline enhanced cell proliferation without toxicity and triggered an antioxidant response, upregulating protective genes including Nrf2 and SOD1. It also shifted microglial cells toward an anti-inflammatory profile, reducing inflammatory markers like iNOS and IL-1β while increasing anti-inflammatory markers like Arg-1 and IL-10. At the highest tested concentration (10 μg/NmL), however, viability dropped and cell death increased — a finding that underscores why dosing precision matters clinically.

A Live Scientific Debate

The study didn’t go unchallenged. Other researchers in the field published a formal comment disputing the clinical translatability of using isolated cell-line models (BV2 microglial cells) to draw conclusions about whole-body ozonated saline therapy. The original authors published a detailed rebuttal in May 2026, defending the BV2 model’s scientific standing by pointing to its use in thousands of peer-reviewed studies, including papers in Nature, Science, and The Lancet. This back-and-forth is a useful reminder that ozonated saline’s mechanism is still being actively debated in the peer-reviewed literature, even as clinical use continues to expand.

Why This Matters

For integrative practices offering ozone therapy, the Russian method’s growing use in the US reflects real practical advantages — patient comfort, simpler logistics, and a gentler dosing profile that may suit patients who can’t tolerate autohemotherapy. But the current evidence base remains mostly preclinical (cell and animal models) and small pilot studies, rather than large randomized controlled trials in humans. The dose-dependent findings in the 2025 Molecules study are a useful clinical caution: what works as a low-dose anti-inflammatory stimulus can become cytotoxic at higher concentrations, reinforcing why ozone concentration and duration protocols matter and shouldn’t be improvised.

Conclusion

The Russian method remains a widely used but still scientifically contested approach within ozone therapy. Ongoing mechanistic research, and the active peer-review debate around it, suggest the field is moving toward better-defined dosing standards rather than settled consensus — worth watching as more rigorous clinical trials emerge.

Sources

  • Armeli, F. et al., “Ozone Saline Solution Polarizes Microglial Cells Towards an Anti-Inflammatory Phenotype,” Molecules, 2025 — Read here
  • Armeli, F. et al., “Reply to Franzini et al. The Translational Medicine Regarding Ozone in Saline Solutions,” Molecules, 2026 — Read here
  • MedOzons, “The Russian Technology of Ozone Therapy” — Read here
Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on The Russian Method: What the Research Says About Ozonated Saline IV Therapy

FDA Grants RMAT Designation to Personalized Stem Cell Therapy for Parkinson’s Disease

By asmithers | Published August 9, 2026

Neural Stem Cell Therapy Neural Stem Cell Therapy or Neuroregenerative Regenerative Medicine injected to regenerate brain tissue for neurodegenerative diseases medical illustration close up macro view. neurosurgery brain cell therapy stock pictures, royalty-free photos & images

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to sasineprocel, Aspen Neuroscience’s investigational autologous cell therapy for Parkinson’s disease. The designation is based on encouraging early safety and activity data from the company’s ongoing Phase 1/2a ASPIRO trial.

Table of Contents

  • What Happened
  • How Sasineprocel Works
  • What the Data Show
  • Why This Matters
  • Conclusion

What Happened

On July 30, 2026, Aspen Neuroscience announced that the FDA granted RMAT designation to sasineprocel (ANPD001), its lead investigational cell therapy for Parkinson’s disease. The designation, created under the 21st Century Cures Act, confers the combined benefits of the FDA’s Fast Track and Breakthrough Therapy programs, including more frequent early interaction with FDA reviewers and potential eligibility for accelerated approval and priority review. Sasineprocel had previously received FDA Fast Track designation; RMAT status builds on that by opening a more structured regulatory dialogue ahead of the company’s planned Phase III study, expected to begin later in 2026.

How Sasineprocel Works

Sasineprocel is an autologous, personalized cell therapy, meaning it’s derived from each patient’s own cells rather than a donor. It’s manufactured by reprogramming a patient’s skin fibroblasts into induced pluripotent stem cells (iPSCs), then differentiating those into dopaminergic neuron precursor cells (DANPCs) — the type of neuron progressively lost in Parkinson’s disease. The cells are surgically delivered directly into the putamen, the brain region where dopamine signaling breaks down in PD, using image-guided delivery technology. The aim is to replace lost neurons and reconstruct disrupted neural circuitry, rather than simply managing symptoms with dopamine-replacement drugs like levodopa.

What the Data Show

The RMAT designation is supported by data from the ongoing Phase 1/2a ASPIRO trial, an open-label, multicohort, multicenter study evaluating sasineprocel in patients aged 50 to 70 with moderate-to-advanced Parkinson’s disease. Through 12 months of follow-up, the trial has shown no serious surgical adverse events, no severe graft-induced dyskinesia (an uncontrolled movement side effect seen with earlier-generation cell therapies), and no symptomatic hemorrhage or infarction. The most common adverse event reported in initial patients was swollen tongue.

Several patients also reduced their daily levodopa dose during the trial, which the company points to as an early signal consistent with disease-modifying activity rather than purely symptomatic benefit. The trial has dosed 15 patients across four cohorts to date, with the two most recent cohorts using a cryopreserved, commercial-ready cell formulation designed to support scalable manufacturing if the therapy advances toward approval.

Why This Matters

Parkinson’s disease currently has no approved treatment that addresses its underlying neurodegeneration — existing therapies manage symptoms but don’t replace the dopamine-producing neurons that are progressively lost. A personalized, patient-derived cell therapy designed to reconstruct that circuitry represents a materially different treatment strategy, and RMAT designation signals the FDA sees enough early promise to fast-track its regulatory pathway. For the broader regenerative and integrative medicine field, it’s also a notable proof point for autologous iPSC-derived cell therapy specifically, an approach that avoids the immunosuppression typically required for donor-derived (allogeneic) cell products.

Conclusion

RMAT designation doesn’t guarantee approval, and sasineprocel remains an investigational therapy years from potential availability. But with Phase III testing expected to begin later this year, this is a program worth tracking closely as it moves from early safety signals toward controlled efficacy data.

Sources

  • BioSpace / PRNewswire, “Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson’s Disease” — Read here
  • NeurologyLive, “FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease” — Read here
  • AllSci, “FDA grants Aspen RMAT designation for cell therapy in Parkinson’s disease” — Read here
Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on FDA Grants RMAT Designation to Personalized Stem Cell Therapy for Parkinson’s Disease

Ozone Therapy Research Roundup: Wound Care, Stroke Recovery, and Cancer Support

By asmithers | Published August 1, 2026

Ozone Therapy Ozone Therapy ozone therapy stock pictures, royalty-free photos & images

Ozone therapy continues to draw growing peer-reviewed research interest as a complementary tool in integrative medicine. Here’s a roundup of recent notable developments spanning a new wearable delivery device, stroke recovery data, and cancer-support applications.

Table of Contents

  • A Wearable Approach to Drug-Resistant Wounds
  • Stroke Recovery Data
  • Ozone as Complementary Cancer Support
  • Faster Healing for Chronic Facial Wounds
  • Why This Matters
  • Conclusion

A Wearable Approach to Drug-Resistant Wounds

Researchers published a study in Advanced Therapeutics describing a smart wearable ozone therapy system designed to treat multidrug-resistant (MDR) bacterial wound infections. Chronic non-healing wounds affect an estimated 10.5 million people in the US and cost Medicare between $28.1 and $96.8 billion annually, with drug-resistant infections a growing complication as antibiotic resistance rises. The device combines ozone’s antimicrobial action with bio-stimulatory healing effects in a single wearable format, an approach the researchers say outperforms conventional single-mechanism treatments like silver dressings or standalone phototherapy in early testing.

Stroke Recovery Data

A 2025 clinical trial published in Frontiers in Medicine compared ozone therapy against traditional antioxidant drugs in patients recovering from acute ischemic stroke, finding that ozone outperformed the comparator on both neurological recovery measures and safety profile. The proposed mechanism centers on ozone’s activation of HIF-1α (hypoxia-inducible factor 1-alpha), which improves oxygen delivery to tissue affected by reduced blood flow — the same pathway researchers point to in ozone’s effects on other vascular and circulatory conditions, including peripheral artery disease and diabetic foot ulcers.

Ozone as Complementary Cancer Support

A 2025 scoping review evaluated medical ozone as a complementary approach for managing cancer-related pain, fatigue, anxiety, and depression, concluding it shows promise with a favorable safety profile when used alongside standard oncology care. This adds to a body of smaller clinical studies from Spanish research groups examining ozone for cancer-treatment-related pelvic pain and chemotherapy-induced peripheral neuropathy, an area that continues to see active clinical trial enrollment.

Faster Healing for Chronic Facial Wounds

A single-arm clinical study published in the Journal of Maxillofacial and Oral Surgery evaluated topical ozone therapy in 11 patients with chronic facial wounds. Pain scores dropped sharply, from a mean of 7.09 on day one to 2.81 by day three, with no reported pain by day seven. Wound size decreased correspondingly, from 14.3 cm² on day one to 0.68 cm² by day seven — a small study, but a striking healing trajectory that supports larger controlled trials.

Why This Matters

Taken together, these studies reflect a field maturing beyond anecdotal use toward device innovation and rigorous outcome measurement. Evidence quality remains moderate by conventional standards — several of the strongest findings still come from small or single-arm studies — but the mechanistic consistency across wound healing, vascular conditions, and inflammatory pain points to biologically plausible pathways (HIF-1α activation, antimicrobial action, immune modulation) that researchers are now testing more rigorously. For integrative and regenerative practices, this is a field worth watching for practice-relevant protocol updates as larger randomized trials mature.

Conclusion

Ozone therapy research is expanding from established uses in pain and wound care into higher-stakes areas like stroke recovery and oncology support. Larger randomized controlled trials will be the next test of whether these early signals hold up at scale.

Sources

  • Advanced Therapeutics (Wiley), “Smart Wearable Ozone Therapy System for Managing Multidrug-Resistant Wound Infections” — Read here
  • Journal of Maxillofacial and Oral Surgery (Springer Nature), “Role of Topical Ozone Therapy in the Management of Chronic Facial Wounds: A Single-Arm Clinical Study” — Read here
  • TopDoctor Magazine, “Ozone Therapy: The Complete Science-Backed Guide (2026)” — Read here
Posted in What We Treat | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Ozone Therapy Research Roundup: Wound Care, Stroke Recovery, and Cancer Support

FDA Advisory Committee to Review Cell Therapy for Duchenne Muscular Dystrophy

By asmithers | Published July 26, 2026

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee meets July 29 to review Capricor Therapeutics’ deramiocel, an investigational allogeneic cell therapy for Duchenne muscular dystrophy. The meeting comes ahead of an August 22 target decision date and follows a prior rejection of the company’s first application.

Table of Contents

  • What’s Happening
  • How Deramiocel Works
  • What the Data Show
  • Why This Matters
  • Conclusion

What’s Happening

On July 29, 2026, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee will convene to review Capricor Therapeutics’ Biologics License Application for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The Federal Register notice confirming the meeting’s final details was amended on July 24, 2026, and the session will be livestreamed for public viewing.

This is Capricor’s second attempt at approval. The FDA rejected the company’s original application, based primarily on Phase 2 data, with a complete response letter citing substantial-evidence and manufacturing (CMC) deficiencies. The agency has since rescinded that letter and is now reviewing a resubmitted application built on additional Phase 3 data, with a PDUFA target action date of August 22, 2026.

How Deramiocel Works

Deramiocel (also known as CAP-1002) is an allogeneic, off-the-shelf cell therapy made from human cardiosphere-derived cells. Administered by infusion, it’s designed to reduce inflammation and support tissue repair in both skeletal and cardiac muscle — the two systems progressively damaged by DMD. If approved, it would be the first therapy to address both the skeletal and cardiac manifestations of the disease in a single product, a distinction that matters given that cardiomyopathy is a leading cause of death in DMD patients.

Deramiocel holds Orphan Drug designation in both the US and EU, Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations in the US, and Advanced Therapy Medicinal Product (ATMP) status in the EU — the last of which may qualify Capricor for a Priority Review Voucher if approved.

What the Data Show

The resubmitted BLA is supported by the Phase 2 HOPE-2 trial and its long-term HOPE-2-OLE extension, along with topline results from the Phase 3 HOPE-3 trial. HOPE-2 showed a 36.2% benefit on a mid-level elbow measure of upper limb function (PUL) versus placebo at 12 months, along with reduced cardiac injury markers (CK-MB and total CK), suggesting less myocardial damage.

HOPE-3 met its primary endpoint, showing a 54% slowing of disease progression on the PUL v2.0 scale, and its key cardiac endpoint showed a 91% slowing in the decline of left ventricular ejection fraction (LVEF) by central cardiac MRI — a marker of heart muscle function. The trial also met additional controlled secondary endpoints.

Why This Matters

For the regenerative and integrative medicine community, this advisory committee meeting is a bellwether moment for cell therapy in a devastating pediatric disease with no treatment that addresses both its muscular and cardiac components. An advisory committee’s recommendation isn’t binding, but it heavily influences the FDA’s final decision and signals how regulators are weighing benefit-risk tradeoffs for allogeneic cell products more broadly. A second look at a previously rejected application, now backed by Phase 3 data, also illustrates how sponsors are increasingly able to iterate through FDA’s regenerative medicine pathways rather than face a single make-or-break review.

Conclusion

The July 29 advisory committee meeting is a critical checkpoint on deramiocel’s path to potential approval by August 22. A positive recommendation would move a first-in-class dual-benefit cell therapy closer to patients; a negative one would raise fresh questions about the regulatory bar for allogeneic cell products in rare pediatric disease.

Sources

  • NeurologyLive, “FDA Advisory Committee Schedules Meeting to Review Deramiocel’s BLA in Duchenne Muscular Dystrophy” — Read here
  • GlobeNewswire / Capricor Therapeutics, “Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy” — Read here
  • Federal Register, “Cellular, Tissue, and Gene Therapies Advisory Committee; Amendment of Notice” — Read here
Posted in What We Treat | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on FDA Advisory Committee to Review Cell Therapy for Duchenne Muscular Dystrophy
941-444-6336 Directions